Short-duration dynamic $[^{18}F]$DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to $[^{18}F]$DCFPyL PET/MR at 120 minutes

Dae‑Myoung Yang1,2,3,11, Ryan Alfano1,4,5, Glenn Bauman4,6, Jonathan D. Thiessen1,3,9, Joseph Chin4,6,7, Stephen Pautler6,7,8, Madeleine Moussa4,10, Jose A. Gomez4,10, Irina Rachinsky4,9, Mena Gaed10, Kevin J. Chung1,2,3, Aaron Ward1,4,5,6 and Ting‑Yim Lee1,2,3,6,9*

Abstract

Purpose: Localized prostate cancer (PCa) in patients is characterized by a dominant focus in the gland (dominant intraprostatic lesion, DIL). Accurate DIL identification may enable more accurate diagnosis and therapy through more precise targeting of biopsy, radiotherapy and focal ablative therapies. The goal of this study is to validate the performance of $[^{18}F]$DCFPyL PET and CT perfusion (CTP) for detecting and localizing DIL against digital histopathological images.

Methods: Multi-modality image sets: in vivo T2-weighted (T2w)-MRI, 22-min dynamic $[^{18}F]$DCFPyL PET/CT, CTP, and 2-h post-injection PET/MR were acquired in patients prior to radical prostatectomy. The explanted gland with implanted fiducial markers was imaged with T2w-MRI. All images were co-registered to the pathologist-annotated digital images of whole-mount mid-gland histology sections using fiducial markers and anatomical landmarks. Regions of interest encompassing DIL and non-DIL tissue were drawn on the digital histopathological images and superimposed on PET and CTP parametric maps. Logistic regression with backward elimination of parameters was used to select the most sensitive parameter set to distinguish DIL from non-DIL voxels. Leave-one-patient-out cross-validation was performed to determine diagnostic performance.

Results: $[^{18}F]$DCFPyL PET and CTP parametric maps of 15 patients were analyzed. SUV_Late and a model combining $K_I$ and $k_4$ of $[^{18}F]$DCFPyL achieved the most accurate performance distinguishing DIL from non-DIL voxels. Both detection models achieved an AUC of 0.90 and an error rate of < 10%. Compared to digital histopathology, the detected DILs had a mean dice similarity coefficient of 0.8 for the $K_I$ and $k_4$ model and 0.7 for SUV_Late.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Conclusions: We have validated using co-registered digital histopathological images that parameters from kinetic analysis of 22-min dynamic ([18F]DCFPyL) PET can accurately localize DILs in PCs for targeting of biopsy, radiotherapy, and focal ablative therapies. Short-duration dynamic ([18F]DCFPyL) PET was not inferior to SUV<sub>late</sub> in this diagnostic task.

Clinical trial registration number: NCT04009174 (ClinicalTrials.gov).

Keywords: ([18F]DCFPyL), Prostate-specific membrane antigen (PSMA), CT perfusion, Tracer kinetic modelling, Dominant intraprostatic lesion (DIL)

Introduction

Localized prostate cancer (PCa) is frequently a multifocal disease [1, 2]. It has been reported in 78% of all cases of radical prostatectomy specimens [3]. The dominant intraprostatic lesion (DIL) is the most prominent cancerous lesion that is the largest in size within the prostate. Identifying DIL is clinically important. The size of DIL showed a strong correlation with prostate-specific antigen (PSA) level and biochemical relapse [4, 5]. DIL is often the site where local recurrence and metastasis originates after treatment [6, 7]. Because of these DIL attributes, radiation therapy involving escalated or boosted doses to DIL has been investigated in several randomized control trials and demonstrated improved biochemical recurrence-free survival [8, 9]. In addition to guiding treatment, DIL localization may improve the diagnostic accuracy of image-guided biopsies and focal ablative therapy [10, 11].

Fluorine-18-labeled prostate-specific membrane antigen (PSMA)-ligand ([18F]DCFPyL) is a newer PCa tracer with improved performance in localizing DIL compared to other PET tracers [12–14]. However, one disadvantage of [18F]DCFPyL is that it takes a long post-injection time for optimal imaging because of the slow net uptake rate constant (K<sub>i</sub> = 0.06–0.20 min<sup>−1</sup>) leading to low tumour-to-background ratio at early times, less than 60 min [15, 16]. Static (single) imaging at least an hour post-injection has been advocated [16–18]. Jansen et al. [16] used dynamic imaging for 60 min and then 90–120-min post-injection and kinetic analysis of acquired dynamic data to derive the tumour-to-blood ratio as a simplified measure of [18F]DCFPyL uptake and showed that it is strongly correlated with the net influx rate constant. Shorter-duration (0–22 min) dynamic PET study with [18F]DCFPyL has also been reported [15]. This latter study showed that net uptake rate constant (K<sub>i</sub>) and dissociation rate constant (K<sub>d</sub>) derived using flow-modified two-tissue compartment (F2TC) kinetics model can robustly detect tumour nodule as identified by prostate sextant biopsy [15]. The F2TC model explicitly takes into account the ingress and egress of [18F]DCFPyL into and from tissue via blood flow [15, 19, 20]. Because of this property, we surmise it can reliably subtract the blood background to allow a more accurate evaluation of the uptake from short (<30 min) data acquisition.

In this study, we compared a short-duration (22 min) dynamic ([18F]DCFPyL) PET scan plus CT Perfusion (CTP) vs 2-h post-injection PET as used in current clinical practice [16–18] to localize DIL using co-registered digital histopathological images as reference. The rationale to limit the acquisition duration of the dynamic scan to 22 min is twofold: 20–30 min is about the longest time for a patient to lie still without discomfort, and we have shown before that kinetic parameters derived from 22 min of dynamic data can detect PCa nodule compared to sextant biopsy even though the method has not been validated against digital pathology of explanted prostate. Dynamic PET and CTP provide complementary molecular and hemodynamic information on DIL and non-DIL prostatic tissue. A secondary goal of this study is to determine whether combining dynamic PET and CTP would better localize DIL than either imaging modality alone.

Methods

Study design

This substudy was one arm of a single-centre (Lawson Health Research Institute, London, ON) two-arm clinical study (NCT04009174) to investigate the feasibility of (1) dynamic PET imaging with either [18F]FCH (N = 25) or [18F]DCFPyL (N = 27) with CT Perfusion on PCa patients and (2) kinetic analysis of the PET dynamic scans to derive kinetic parameters to localize DIL using co-registered digital histopathological images as reference. The study was approved by the Institutional Research Ethics Board. All participants in this study provided written informed consent. Subjects who had untreated biopsy-proven localized PCa were enrolled in this study. Inclusion criteria were: aged 18 years or older; biopsy-confirmed PCa; suitable for and consenting to radical prostatectomy for treatment. Exclusion criteria were: prior therapy including hormone therapy for PCa, use of 5-alpha reductase inhibitors—finasteride or dutasteride—within 6 months of study date; unable to comply with all pre-operative imaging; prostate size exceeding 50% of whole-mount pathology slides; allergy to CT contrast agent; sickle cell disease or other anemias; impaired renal function (estimated GFR < 60 mL/
min/1.73 m$^2$); residual bladder volume $>$ 150 cc (determined by post-void ultrasound); hip prosthesis and/or vascular graft that are MRI incompatible or other metallic objects within the pelvis; contraindication to MRI, such as a pacemaker or other electronic implants, known metal in orbits and cerebral aneurysm clips. As this sub-study was a feasibility study on the two aforementioned goals, sample size was chosen based on availability of radical prostatectomy patients at our site, and no formal calculation was done.

Participating patients in this sub-study, from March 2016 to January 2018, underwent the pre-operative imaging session consisting of dynamic $[^{18}F]$DCFPyL PET/CT, CTP, and PET/MR imaging. Dynamic $[^{18}F]$DCFPyL PET/CT was performed first, followed by CTP using a hybrid PET/CT scanner (Discovery VCT, GE Healthcare, Waukesha, WI, USA). At 2-h post-injection of $[^{18}F]$DCFPyL, static PET and MR imaging were performed with a hybrid PET/MR scanner (3 T Biograph mMR, Siemens, Malvern, PA, USA). All patients underwent radical prostatectomy within 6 weeks of all preoperative imaging sessions. The explanted gland with implanted fiducial markers was imaged with T2-weighted (T2w)-MRI and then processed using spatially accurate whole-mount sectioning [21]. Cross sections of the explanted gland spanning the entire mid-prostate were stained with haematoxylin and eosin (H&E) imaging with digital histopathology.

22-min dynamic $[^{18}F]$DCFPyL PET/CT imaging
The tracer $[^{18}F]$DCFPyL was purchased from Centre for Probe Development and Commercialization, (Hamilton, ON). Dynamic PET imaging was performed on a Discovery VCT (GE Healthcare, Waukesha, WI, USA) PET/CT scanner. A CT scan was taken with patients lying supine on the patient couch for localization of the prostate and attenuation correction of PET images. The dynamic $[^{18}F]$DCFPyL PET scan covered the whole prostate up to the iliac crest, image-derived arterial time–activity curve required for kinetic analysis of dynamic PET data was acquired from an internal iliac artery to generate parametric maps. Starting at the injection of 325 MBq of $[^{18}F]$DCFPyL as a bolus into an antecubital vein, the dynamic PET scan acquired over 22 min the following number of volumes at each of seven framing intervals: 11 at 10 s, 5 at 20 s, 4 at 40 s, 4 at 60 s, and 4 at 180 s. Each volume comprised of forty-seven 3.27-mm-thick slices. Early time standardized uptake (SUV$_{Early}$) in g/mL was measured as the average of the last four dynamic PET volumes (10–22 min post-injection).

The acquired dynamic volumes were analyzed to generate parametric maps of the whole prostate. We calculated influx rate constant ($K_i$) in mL/min/g, efflux rate constant ($K_e$) in min$^{-1}$, binding rate constant ($k_3$) in min$^{-1}$, dissociation rate constant ($k_4$) in min$^{-1}$, net uptake rate constant from plasma ($K_u$) in mL/min/g, and distribution volume (DV) in g/mL maps by deconvolving the arterial time–activity curve from tissue time–activity curve using F2TC model [19]. The tissue time–activity curve of each voxel was smoothed by a 3-by-3 mean filter with those from the immediate neighbouring pixels in the same slice.

CT perfusion (CTP) imaging
Free-breathing CTP scan was performed immediately after the dynamic PET scan without moving the patient. The CTP images were acquired over 3 min using a shuttle mode where two contiguous 4-cm sections of the pelvis covering the prostate and both internal iliac arteries, identified from the CT localization and attenuation correction scan, were alternately scanned starting 6 s after a bolus injection of contrast agent (Isovue 370, Bracco Diagnostic Inc., NJ, USA) at a rate of 3 mL/s and a dosage of 0.7 mL/kg into an antecubital vein. The CTP images were acquired using 5-mm-thick slices, 120 kVp and 50 mAs in two phases: the first phase, at intervals of 2.8 s for first 1 min; the second phase, every 15 s for the next 2 min.

The acquired dynamic CT volumes were co-registered using non-rigid image registration (GE healthcare) to minimize misregistration from breathing motion before functional maps, including blood flow (BF) in mL/min/100 g, blood volume (BV) in mL/100 g, mean transit time (MTT) in second, vessel permeability surface product (PS) in mL/min/100 g, and contrast delay time (T0) in second, and were generated with CT perfusion software (GE Healthcare) [22].

Two-hour post-injection PET/MR
After the CTP scan, the patient was allowed to rest, lying supine on a couch, in a quiet injection waiting room. At 2-h post-injection, after emptying the bladder, a static PET image of the prostate using limits established with the prior dynamic PET/CT scan was acquired over 15 min on a 3-T Biograph mMR (Siemens, Malvern, PA, USA) hybrid PET/MR scanner [23]. PET images were reconstructed with an ordered subset expectation maximization (OSEM) algorithm with 21 subsets, 3 iterations, and a 4-mm Gaussian filter. Reconstructed resolution was $2.09 \times 2.09 \times 2.03$ mm$^3$. MRI was acquired simultaneously with a prostate endorectal receive coil (Medrad), flexible body array (mMR Body), and spine array (mMR Spine). Attenuation correction maps were generated from a 2-point Dixon acquisition segmented for water, fat, and air. T2-weighted MRI included 2D transverse, sagittal, and coronal acquisitions as well as a
3D acquisition. Two-hour post-injection SUV (SUV\text{\text{\scriptsize Late}}) maps in g/mL were measured from the acquired images.

**Image registrations and analysis**

After surgical resection, the prostate specimen was placed in 10% buffered formalin and marked with fiducial markers [21]. The specimen was then temporarily placed in a perfluoropolyether oil (Christo-Lube, Lubrication Technology, Franklin Furnace, OH, USA)-filled container for imaging. Ex vivo T2w-MRI was performed with a 3-T Discovery MR750 scanner (GE Healthcare, Waukesha, WI, USA). The oil provided a black background to minimize boundary artefacts in the MR images of the explanted prostate. After fixing in formalin for 48 h, the specimen was processed as per the standard pathology grossing protocol at our institution and submitted for routine processing, paraffin embedding, and reporting. Whole-mount 4-μm-thick H&E-stained histology cross sections spanning the entire midprostate were then digitized for contouring and histopathological scoring by pathologists.

In order to correlate all PET, CT, and MR maps to cancerous nodules identified in digital histopathological images of the explanted prostate, a registration pipeline, as shown in Fig. 1, was developed. The ex vivo T2w-MRI was used as the bridge to co-register ex vivo digital histopathology to in vivo PET, CT, and MR. All these images were registered using a non-rigid or rigid-affine registration to compensate for any shrinkage of the explanted prostate. Histology and ex vivo MR co-registration was done using automatic non-rigid registration with the marked fiducial markers and anatomical structures/landmarks [21]. Co-registration of ex vivo MRI and in vivo PET/MRI was done using user-identified homologous anatomical landmarks (i.e. benign prostatic hyperplasia nodules, urethra, calcifications, etc.) via a manual thin plate spline non-rigid registration [11]. Co-registration of CTP average map and ex vivo T2w-MRI was done using anatomical landmarks via manual rigid-affine registration in ITK-SNAP ([www.itk-snap.org](http://www.itk-snap.org)) [24]. PET-CTP co-registration was achieved by registering the CT images acquired for attenuation correction of dynamic PET and CTP average maps with the automatic 3D rigid-affine registration module—General Registration—in 3D slicer ([www.slicer.org](http://www.slicer.org)) [25]. After co-registration of all PET and CTP parametric maps with digital histopathological images, regions of interest were drawn on the latter images, to encompass the DIL and the entire prostate outside the DIL (non-DIL) by pathologists (contoured by MG and verified by MM and JAG). The DIL was identified as the largest cancerous lesion within the histopathological images. These ROIs were superimposed on all corresponding PET and CTP maps to generate voxel and volumetric data for DIL and non-DIL prostatic tissue. Additionally, anatomical features such as calcifications and urethra in the co-registered PET, MR, and CTP images were compared to the digital histopathological images to determine the error of registration which was found to be between 3 mm (CT and MR) and 5.5 mm (one PET voxel).

**Statistical analysis**

Statistical analyses were performed in SPSS Statistics 27 (IBM Analytics, Armonk NY), using two-sided statistical testing with significance accepted at $P<0.05$. Descriptive statistics were presented as mean and SD or as median and range (min to max). Differences between DIL and non-DIL imaging parameters in DIL and non-DIL ROIs

---

**Fig. 1** Registration pipeline. CT Computed tomography, T2w transverse relaxation time weighted, PET positron emission tomography, MR magnetic resonance, BF blood flow, BV blood volume, MTT mean transit time, PS vessel permeability surface product, $T_c$ contrast delay time, $K_i$ influx rate constant, $k_2$ efflux rate constant, $k_3$ binding rate constant, $k_4$ dissociation rate constant, $K_i$ net uptake rate constant, $DV$ distribution volume, $SUV$ standardized uptake value.
were compared using the Wilcoxon signed-rank test with Bonferroni correction for multiple comparisons. Voxelwise multivariable logistic regression with backward elimination was used to determine the most accurate model of $[^{18}F]$DCFPyL PET and CTP parameters from a subset, each of which attained $P<0.05$ in univariable Wilcoxon signed-rank testing, to distinguish DIL from non-DIL tissue. We also performed leave-one-patient-out cross-validation to validate the selected logistic regression model for voxel-wise analysis and reported the average and standard error of error rate (ER), false-positive rate (FPR) and false-negative rate (FNR), area under the receiver operating characteristic curve (AUC) of all folds.

Results

Patients

Twenty-seven male patients with biopsy-proven PCa were enrolled in the $[^{18}F]$DCFPyL arm of a clinical trial (NCT04009174, Fig. 2). A subset of 19 patients completed both imaging sessions—$[^{18}F]$DCFPyL PET/CT, CTP, and $[^{18}F]$DCFPyL PET/MR and also underwent radical prostatectomy. Of those, 15 had analyzable digital histopathological images from the mid-section of the gland. Figure 2 shows the patient flow through the study. The detailed clinical–pathological characteristics of 15 patients (median age 63 year; range 53–68 year) who were included in this study are listed in Table 1.

| Table 1 | Clinical–pathological characteristics of patients and tumours ($n=15$) |
|---------|-------------------------------------------------------------------|
| Age [y] | 62.1 ± 4.1 (53–68)* |
| Weight [kg] | 88.8 ± 11.4 (65–109)* |
| Height [cm] | 177.4 ± 6.1 (170–191)* |
| PSA [ng/mL] | 94 ± 6.3 (3.5–25.5)* |
| Injected $[^{18}F]$DCFPyL activity [MBq] | 312.4 ± 15.9 (280.8–348.2)* |
| Histology—n(%) | |
| Adenocarcinoma | 15 (100) |
| pT Stage—n(%) | |
| T2c | 7 (46.7) |
| T3a | 7 (46.7) |
| T3b | 1 (6.7) |
| pN Stage—n(%) | |
| N0 | 15 (100) |
| N1 | 0 (0) |
| NX | 0 (0) |
| pM Stage—n(%) | |
| M0 | 15 (100) |
| M1 | 0 (0) |
| MX | 0 (0) |
| Gleason score of DIL—n(%) | |
| 6 (3+3) | 1 (6.7) |
| 7 (3+4) | 6 (40.0) |
| 7 (4+3) | 5 (33.3) |
| 9 (5+4) | 3 (20.0) |

Data are the number of patients with the percentage in parentheses unless otherwise indicated. $[^{18}F]$DCFPyL 2-(3-{1-Carboxy-5-{[6-[^{18}F]fluoro-pyridine-3-carbonyl]-amino}}pentyl)-ureido)-pentanedioic acid, PSA prostate-specific antigen, pT primary tumour, pN lymph node, pM distant metastasis, DIL dominant intraprostatic lesion

*Data are means ± standard deviation, with the range in parentheses.
mL, \( P < 0.001 \), and SUV_{Late} (median 1.55 vs. 0.67 g/mL, \( P < 0.001 \)).

Among these parameters from PET and CTP, the combination of \( K_i \) and \( k_4 \) was the most accurate model to distinguish DIL from non-DIL voxel using multivariable logistic regression with backward elimination (\( P < 0.001 \)). If only significant CTP parameters were used, the BF and MTT model was the most accurate model (\( P < 0.001 \)).

Cross-validation and diagnostic performance

Four DIL detection models—\( K_i \) and \( k_4 \); BF and MTT; SUV_{Early} and SUV_{Late}—were validated using leave-one-patient-out cross-validation. The ER, FPR, FNR, and AUC obtained for each model are shown in Fig. 3. \( K_i \) and \( k_4 \) were the most accurate and stable model to detect DIL. It had ER of 9.9 \( \pm \) 2.8\%, FPR of 9.1 \( \pm \) 3.1\%, FNR of 9.6 \( \pm \) 3.0\%, and AUC of 90.4 \( \pm \) 0.2\%. BF and MTT model showed ER, FPR, FNR, and AUC of 45.5 \( \pm \) 6.8\%, 19.3 \( \pm \) 3.6\%, 74.8 \( \pm \) 0.2\%, respectively. SUV_{Early} model showed ER, FPR, FNR, and AUC of 15.7 \( \pm \) 5.6\%, 15.3 \( \pm \) 6.2\%, and 12.7 \( \pm \) 5.3\%, 84.7 \( \pm \) 0.5\%. While for SUV_{Late}, ER, FPR, FNR, and AUC of 9.8 \( \pm \) 2.3\%, 8.7 \( \pm \) 2.4\%, 11.9 \( \pm \) 4.3\%, 90.5 \( \pm \) 0.3\%. AUC of \( K_i \) and \( k_4 \) versus SUV_{Late} was not significantly different, but both were better than SUV_{Early} and BF and MTT. FNR was similar among all models except that BF and ER were significantly worse than \( K_i \) and \( k_4 \). For FPR and ER, only BF and MTT were significantly worse than the other models.

Dice similarity coefficient which gauged the similarity in size and location between the DIL detected by each model against that delineated by pathologists (MM,MG) on the digital histopathological images was 0.8 \( \pm \) 0.1, 0.4 \( \pm \) 0.1, 0.7 \( \pm \) 0.1, and 0.7 \( \pm \) 0.1, respectively, for \( K_i \) and \( k_4 \) model, BF and MTT model, SUV_{Early} and SUV_{Late}.

Discussion

In this study, we investigated using dynamic \([^{18}\text{F}]\)DCFPyL PET kinetic parameters, CTP parameters, and SUV_{Late} to localize DIL in 15 patients and validated the developed method against digital histopathological images. Our analysis showed that \( K_i \) (net uptake rate constant of \([^{18}\text{F}]\)DCFPyL from plasma) and \( k_4 \) (dissociation rate constant of \([^{18}\text{F}]\)DCFPyL after binding to PSMA on PCa cells) model from 22-min dynamic PET was the more accurate and stable model to detect and localize DIL with excellent diagnostic performance versus digital histopathology as validated using leave-one-patient-out cross-validation (Fig. 3).

Figure 3 shows three important aspects of the results: (1) SUV_{Late} showed better DIL detection results than SUV_{Early} (AUC 90.5 \( \pm \) 0.3\% vs. 84.7 \( \pm \) 0.5\%, \( P < 0.001 \)), (2) \( K_i \) and \( k_4 \) model also showed better results than SUV_{Early} (AUC 90.4 \( \pm \) 0.2\% vs. 84.7 \( \pm \) 0.5\%, \( P < 0.001 \)), and 3. \( K_i \) and \( k_4 \) model from 22-min dynamic scan achieved comparable results to the 2-h post-injection SUV_{Late} (AUC 90.4 \( \pm \) 0.2\% vs. 90.5 \( \pm \) 0.3\%, \( P > 0.05 \)). These results agree with the literature recommendation that if SUV is used to detect PCa, the imaging has to be performed at > 1 h post-injection [16–18]. Furthermore, the \( K_i \) and \( k_4 \) model achieved the best dice similarity coefficient and FNR against SUV_{Early} and SUV_{Late}. This is significant for image-guided biopsies and local radiation therapy (e.g. focal ablative therapy or radiation boost) because imaging modality with the lowest tumour omission is preferred. In terms of avoiding overtreatment of non-tumour tissue,
the $K_i$ and $k_4$ model and SUV\textsubscript{Late} had the same FPR which was smaller than SUV\textsubscript{Early}.

Figure 4 shows qualitatively the distinction of DIL from non-DIL tissue using the different parametric maps in a patient. It is noteworthy that the linear classifier from the $K_i$ and $k_4$ model shows that DIL had high net uptake rate constant ($K_i$) of the tracer and low tracer dissociation rate constant from PSMA once bound ($k_4$). This shows that even with favourable kinetics, SUV acquired at a short time post-injection, as was SUV\textsubscript{Early} in this study, cannot reliably differentiate DIL from non-DIL tissue because tissue uptake was dominated by high BF and BV (see Fig. 4) or the high blood background. SUV measured with a single static image at a fixed time after injection cannot differentiate the different processes driving the tracer uptake including: tracer delivery to and washout from tissue via blood flow, bidirectional exchange between vessels and tissue, and binding to and dissociation from the target. The F2TC model used in the kinetic analysis of dynamic $^{18}$FDCFPyL data in this study was able to separate the different uptake processes, particularly removing the blood background, hence provided a better characterization of the different uptake of the tracer in DIL vs. non-DIL tissue at early times post-injection. Even though our short-duration (22 min) study may result in biased estimates of the uptake parameters: $K_i$, $k_3$, $k_4$, and DV, nevertheless two of the parameters, $K_i$ and $k_4$, were able to reliably distinguish between DIL and non-DIL with performance non-inferior to that of SUV\textsubscript{Late}. From the clinical perspective, the short duration would increase the throughput of $^{18}$FDCFPyL studies to detect and localize DIL.

In this study, we showed that among the four clinical methods for identifying DIL, dynamic PET-derived $K_i$ and $k_4$ and SUV\textsubscript{Late} are equivalent and better than SUV\textsubscript{Early} or CTP and CTP is the worst. In comparing $K_i$ and $k_4$ versus SUV\textsubscript{Late}, the former has the advantage that delayed (2-h post) imaging is not required simplifying scheduling and increasing convenience to patients. We also found that CTP parameters did not add to the diagnostic performance of PET in distinguishing DIL from non-DIL tissue (results not shown). A possible explanation is that blood flow is already subsumed in the net uptake rate constant from plasma ($K_i$). Using just CTP parameters, the BF and MTT model showed AUC of 74.8 ± 0.2%, which was lower than the other models based on $^{18}$FDCFPyL. Nevertheless, these results were still comparable to the AUC of multi-parametric MR (mp-MRI), which ranged from 68 to 77% [26–28]. An important advantage of CT perfusion is that it can be easily incorporated into current clinical CT
scanning protocols used in diagnosis and treatment follow-up by adding only a couple of minutes in scanning time and being less expensive than either mp-MRI or PET. Additionally, CTP imaging lends itself to integration with existing CT planning processes for radiation treatment, potentially enabling differential tumor volume boosting [29].

This study has limitations. First, the number of enrolled patients in this study was small and was further reduced by various reasons as discussed in ‘Results’ raising the possibility of selection bias. As such, the results obtained must be interpreted with caution but warrant confirmation with another study with a larger number of patients. Second, we used binomial logistic regression limiting our detection method to two tissue types—DIL and non-DIL. A trinomial logistic regression would allow separate of three tissue types—DIL, non-DIL cancer nodules, and benign prostatic tissue. The small number of patients available precluded a reliable investigation of this possibility. However, if the goal is to identify DIL for boosting the radiation dose and more precise targeting of biopsy, a two-tissue type separation method would be sufficient for this purpose.

Conclusion
Using kinetic analysis to remove blood background, we showed that the kinetic parameters $k_1$ and $k_2$ derived from a 22-min dynamic $^{[18]}$FDCFPyL PET can detect DIL as accurately as SUV measured at 2-h post-injection. As the method can improve the throughput and logistics of using $^{[18]}$FDCFPyL PET for the management of prostate cancer, further study with larger sample size is warranted.

Authors’ contributions
GB, JC, SP, MM, JAG, IR, AW, and T-YL helped in study concept. D-MY, GB, JC, SP, MM, JAG, IR, AW, and T-YL contributed to study design. D-MY, RA, GB, IR, AW, and T-YL collected the imaging data. JC and SP collected the surgical data. MM, JAG, and MG collected the pathology data. D-MY, RA, GB, KJC, AW, and T-YL analysed the data. D-MY, GB, and T-YL drafted the manuscript. All helped in manuscript revision and approval of content.

Funding
The project was supported in part by a Leading-Edge Fund Grant (#11358) from the Canada Foundation for Innovation, Ontario Innovation Fund, the Ontario Institute for Cancer Research (OICR), and the Canadian Institute for Health Research (CIHR).

Availability of data and materials
All reasonable request for research data from this study will be granted and provided it is used for academic purposes.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (University of Western Ontario Research Ethics Boards) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication
All research participants consent to publication of data acquired in the approved study.

Informed consent
Informed consent was obtained from all individual participants included in the study.

Competing interests
The CT perfusion software is licensed to GE Healthcare (Ting-Yim Lee). All other authors have no competing interests to report.

Author details
1 Department of Medical Biophysics, The University of Western Ontario, London, ON, Canada. 2 Robarts Research Institute, The University of Western Ontario, London, ON, Canada. 3 Imaging Program, Lawson Health Research Institute, 750 Base Line Road E, London, ON N6C 2R5, Canada. 4 London Health Sciences Centre, London, ON, Canada. 5 Baines Imaging Research Laboratory, London, ON, Canada. 6 Department of Oncology, The University of Western Ontario, London, ON, Canada. 7 Department of Surgery, The University of Western Ontario, London, ON, Canada. 8 St. Joseph’s Health Care, London, ON, Canada. 9 Department of Medical Imaging, The University of Western Ontario, London, ON, Canada. 10 Department of Pathology and Laboratory Medicine, The University of Western Ontario, London, ON, Canada. 11 Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA.

Received: 22 June 2021 Accepted: 27 September 2021
Published online: 15 October 2021

References
1. Boutron PC, Fraser M, Harding NJ, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015. https://doi.org/10.1038/ng.3315.
2. Espiritu SM, Liu LY, Rubanova Y, et al. The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell. 2018. https://doi.org/10.1016/j.cell.2018.03.029.
3. Karavitakis M, Winkler M, Abel P, et al. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011. https://doi.org/10.1038/pcc.2010.16.
4. Carvalhal GF, Daudt SN, Kan D, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology. 2010. https://doi.org/10.1016/j.urology.2009.11.056.
5. Eichelberger LE, Koch MO, Eble JN, et al. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol. 2005. https://doi.org/10.1038/modpathol.38004-05.
6. von Eyben FE, Klijnen T, Kangasmaki A, et al. Radiotherapy boost for the dominant intraprostatic cancer lesion—a systematic review and meta-analysis. Clin Genitourin Cancer. 2016. https://doi.org/10.1016/j.clgc.2015.12.005.
7. Zamboglou C, Klein CM, Thomann B, et al. The dose-distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiat Oncol. 2018. https://doi.org/10.1186/s13014-018-1014-1.
8. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007. https://doi.org/10.1016/S1470-2045(07)70143-2.
9. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005. https://doi.org/10.1001/jama.294.10.1233.
10. Drost FJ, Osse DS, Nieuwer D, et al. Prostate MRI with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD012663.pub2.
11. Alfano R, Bauman GS, Liu W, et al. Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging. Radiother Oncol. 2020. https://doi.org/10.1016/j.radonc.2020.08.008.

12. True LD, Chen DL. How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer? Clin Cancer Res. 2021. https:// doi.org/10.1158/1078-0432.CCR-21-0749.

13. Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F-fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020. https://doi.org/10.1148/radiol.2020191689.

14. Galgano SJ, Valentin R, McConathy J. Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer. Transl Androl Urol. 2018. https://doi.org/10.21037/tau.2018.06.09.

15. Yang DM, Li F, Bauman G, et al. Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18F]DCFPyL-PET: comparison to [18F] fluorocholine-PET. EJNMMI Res. 2021. https://doi.org/10.1186/s13550-020-00735-w.

16. Jansen BH, Yaqub M, Voortman J, et al. Simplified methods for quantification of 18F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.227520.

17. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021. https://doi.org/10.1097/JU.0000000000001698.

18. Wondergem M, van der Zant FM, Broos WA, Knol RJ. Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.258574.

19. Yang DM, Palma D, Louie A, et al. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: a prospective quantitative hybrid 18F-fluoroethylglucose-poster emission tomography and CT perfusion study. J Med Imaging Radiat Oncol. 2019. https://doi.org/10.1111/1754-9485.12807.

20. Yang DM, Palma D, Louie A, et al. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study. Radiat Oncol. 2021. https://doi.org/10.1186/s13014-021-01747-z.

21. Gibson E, Cruklecy C, Gaed M, et al. Registration of prostate histology images to ex vivo MR images via strand-shaped fiducials. J Magn Reson Imaging. 2012. https://doi.org/10.1002/jmri.23767.

22. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q J Nucl Med. 2003;47(3):171–87.

23. Delso G, Fürst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011. https://doi.org/10.2967/jnumed.111.092726.

24. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006. https://doi.org/10.1016/j.neuroimage.2006.01.015.

25. Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012. https://doi.org/10.1016/j.mrini.2012.05.001.

26. Groenendaal G, Borren A, Moman MR, et al. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys. 2012. https://doi.org/10.1016/j.ijrobp.2011.07.021.

27. Metzger GJ, Kalavagunta C, Spilseth B, et al. Development of quantitative multiparametric MR models for prostate cancer detection using registered correlative histopathology. Radiology. 2016. https://doi.org/10.1148/radiol.2015151089.

28. Granapragasam JV, Barret T, Starling L, et al. Use of the PHI assay as a first line triaging test in an image-guided prostate cancer diagnostic pathway. The PHI in Refining MRI (PRIM) study. Eur Urol Suppl. 2019. https://doi.org/10.1016/j.eursup.2019.04.015.

29. Monninkhof EM, Van Loon JW, Van Vulpen M, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol. 2018. https://doi.org/10.1016/j.radonc.2017.12.022.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.